PLYX

Polaryx Therapeutics, Inc.

Polaryx Therapeutics, Inc. (PLYX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -15.7%
Price Return 12M -94.9%
Catalyst Signal 0.00
Market Cap $83.8M
TTM Revenue N/A
Price / Sales N/A
ROE -96.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) D+ (1.8) D+ (1.7) C- (2.1) C+ (2.6) C (2.2)
2026-11-07 C+ (2.5) C- (1.9) D+ (1.7) C- (1.9) C+ (2.7) C- (2.1)
2026-10-31 C+ (2.5) D+ (1.8) D+ (1.8) D+ (1.5) C+ (2.7) C- (2.1)
2026-10-24 C+ (2.5) C- (1.9) D+ (1.8) D+ (1.7) C+ (2.6) C- (2.1)
2026-10-17 C+ (2.5) D+ (1.8) D+ (1.8) D+ (1.5) C+ (2.6) C- (2.1)
Page 1 of 4